Since the legalization of medical cannabis in 2016, Australia has been steadily developing its marijuana industry — and it’s been attracting attention from international players and investors.

With a quickly growing population of over 25 million people and a robust agriculture industry, the country is positioned to mould itself into a major force in the international cannabis space.


Here the Investing News Network takes a look at how the cannabis industry in Australia has been shaping up since legalization and what these developments could mean for investors. Read on to see what you need to know about investing in cannabis down under.

How does the cannabis market fare in Australia? Read our FREE outlook report on Australian cannabis investing!

 
Get an in depth market report for free!
 

Australia cannabis investing: Market overview

As mentioned, Australia’s parliament passed legislation to allow the cultivation of cannabis for medicinal and research purposes in 2016 by amending the Narcotic Drugs Act 1967. Cannabis companies have been cropping up in the country since then.

While the cannabis industry is still young, Australia’s agriculture sector is well established. According to the Australian Bureau of Agricultural and Resource Economics and Sciences, agriculture production is valued at AU$61 billion and is one of the largest contributors to the nation’s GDP. The country’s agriculture export prowess means that it may be able to capitalize on the trend of moving medical marijuana products internationally.

Recreational cannabis use isn’t legal in Australia, but according to the Australian Institute of Health and Welfare (AIHW), cannabis is the most widely used illicit drug in the country. In a report, AIHW notes that 85 percent of Australians now favour cannabis use for medical purposes, up from 69 percent in 2013.

Medical cannabis in the country is overseen by the Office of Drug Control, which issues three types of licences: research, manufacturing of a drug or product and cultivation or production of medical cannabis. As of November 2020, a total of 13 research licences, 29 cannabis cultivation or production licences, and 33 manufacturing licences were held by medical cannabis companies in Australia.

Medical cannabis users do face a bit of difficulty accessing the drug. Patients can only receive medicinal cannabis products via a specialist appointment and then may have to wait up to a month for government approval.

Some of the largest names in Canada’s cannabis landscape, such as Aurora Cannabis (NYSE:ACB,TSX:ACB) and Canopy Growth (NYSE:CGC,TSX:WEED), have substantial stakes in Australian companies. In 2018, Canopy launched Spectrum Cannabis Australia, a medical cannabis company.

In early 2019, Spectrum received its first shipment of medical cannabidiol (CBD) oil and began sales. Its goal is to support patients through imports until domestic facilities are working at full capacity.

How does the cannabis market fare in Australia? Read our FREE outlook report on Australian cannabis investing!

 
Get an in depth market report for free!
 

Australia cannabis investing: How to invest

Since the country’s cannabis space is still in its early stages, the Australian market hasn’t yet reached its peak. However, more cannabis stocks are expected to list on the Australian Securities Exchange (ASX) this year, which means more investment opportunities.

Elixinol Global (ASX:EXL) was formed in 2018 when Colorado-based Elixinol partnered up with Hemp Food Australia to form an international brand and launch an initial public offering.

While Hemp Food Australia manufactures and distributes hemp food and skincare products, Elixinol is a retail provider on the CBD side of things, with dietary supplements and topical cannabis products. Elixinol has fcoused on building a solid global footprint with operations in the Americas, Europe and Asia. In its Q3 2020 quarterly report, Elixinol said that revenues across business units increased by 18 percent over the previous quarter, with 25 percent of global sales coming from e-commerce sales and 65 percent of total global sales associated woith higher margin products.

Another big player in the Australian space is Cann Group (ASX:CAN,OTC Pink:CNGGF). Established in 2014, Cann Group was the first cannabis company to be issued a cannabis research licence and the first to be issued a medical cannabis cultivation licence by the Australian government.

It’s since worked to develop and supply cannabis, cannabis resin and medical cannabis products to patients for everything from multiple sclerosis to chronic pain.

In an agreement announced in November 2020, Cann Group said that it had secured a AU$50 million loan from the National Australia Bank to fund first stage expansion of its new Mildura growing facility in Victoria. Once completed, Cann Group will have the capacity to produce 12,500 kilograms per year of dry cannabis flower for for international and domestic medical cannabis markets. This move puts Cann Group ahead in terms of production in a market that is still largely driven by imports.

There is also Althea Group (ASX:AGH), a producer, supplier and exporter of pharmaceutical-grade medicinal marijuana which received its licence to cultivate medical cannabis in 2018. Currently, the company operates in regulated medical cannabis markets including Australia and the UK.

How does the cannabis market fare in Australia? Read our FREE outlook report on Australian cannabis investing!

 
Get an in depth market report for free!
 

In late 2020, the company announced it had received approval to sell cannabis products in Germany. The approval makes Althea the first commercial supplier of made-in-Australia medical cannabis products to be sold in Germany, a market expected to be worth approximately AU$2.4 billion by 2025, reported The Market Herald.

Althea has made outreach an important part of its business model. The company launched the Althea Concierge platform, a free online service that allows healthcare professionals to access treatment plans with information about specific Althea marijuana products.

Australia cannabis investing: Future outlook

In 2019, the medical cannabis industry in Australia was valued at a slight US$171.7 million, but a forecast from Prohibition Partners, a market consultancy for the cannabis sector, projects huge growth in value over the next 5 years. By 2024, the total legal cannabis market in Australia is expected to hit US$1.23 billion.

Australia’s domestic market may be “somewhat capped by the region’s population,” Prohibition Partners points out that “overseas exports represent an opportunity for the region to significantly increase its value and establish a strong presence in the global market.”

Alongside the legalization of medical cannabis was the legalization of overseas exports in 2018, and Australia has big plans for the growth of its international presence. “We’d like to be potentially the world’s number one supplier,” said Australian Health Minister Greg Hunt on a local radio station.

Because of its proximity to the region, Australia is also well positioned to break into the burgeoning Asian market, which has become more attractive since the recent legalization of medical marijuana in South Korea and Thailand.

In response, some companies in Australia, such as Cann Group, have already made investments towards building larger facilities to meet the demand.

There’s also been talk about the legalization of cannabis for recreational use in response to growing support for complete cannabis legalization across the country. One of Australia’s internal territories, the Australian Capital Territory became one of the first states in the country to make it legal to grow or possess cannabis for personal use.

Overall, while recreational marijuana is still illegal in Australia, the growth of the country’s medical cannabis industry — and the Australian marijuana companies that exist within it — will continue to grow investment opportunities.

Don’t forget to follow us @INN_Australia for real-time news updates!

Securities Disclosure: I, Danielle Edwards, hold no direct investment interest in any company mentioned in this article.

How does the cannabis market fare in Australia? Read our FREE outlook report on Australian cannabis investing!

 
Get an in depth market report for free!
 

As investors continue to prioritize cannabis opportunities in the US, market watchers expect mergers and acquisitions (M&A) to play a role in the future for Canadian companies.

A consolidation trend has been expected in the Canadian cannabis space for some time now based on the size of the market compared to the number of operations in the country.

Keep reading... Show less

The product will include polyphenols known to have significant health benefits.

BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) has reached an important milestone in its development program of additional Nutraceuticals. The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside. These compounds are the major polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil. Importantly, the BioHarvest olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low calorie count per serving.

Keep reading... Show less

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today that it will report financial results for the fourth quarter and full year ended December 31 st , 2020 on Thursday March 25 th , 2021 before the market opens.

The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights on Thursday March 25 th , 2021 at 8:30am Eastern Time (7:30am Central Time).

Keep reading... Show less

 Canopy Growth Corporation (TSX: WEED) (NASDAQ: CGC) (“Canopy Growth” or “the Corporation”) announced today that EVP & CFO Mike Lee will be participating in a fireside chat at the BofA Securities Virtual Consumer & Retail Technology Conference on Thursday, March 11, 2021 at 9:30am ET .

Keep reading... Show less

Hill Street Beverage Company Inc. (TSXV: BEER) (“Hill Street” or the “Company”). The Company announces that further to its press release dated March 2, 2021, it has obtained TSX Venture Exchange approval to extend the closing date of its previously announced private placement of units (“Units”) until April 7, 2021. Each Unit is comprised of one (1) common share and one (1) warrant, exercisable for one common share at price of $0.11 per share, for a period of three (3) years from the date of Closing. The Company applied to extend the date of closing to allow a greater number of interested investors to participate.

For more information regarding the Company or the offering, please contact ir@hillstreetbevco.com, or

Keep reading... Show less